嵌合抗原受体T细胞在恶性血液疾病中的治疗

icartab

技术资料下载地址: http://www.ncbi.nlm.nih.gov/pubmed/26874466
文献来源： Transfus Apher Sci
Chimeric antigen receptor T cell treatment in hematologic malignancies.
Abstract
Adoptive transfer of T cells that have genetically engineered chimeric antigen receptors (CARs) is an encouraging treatment modality in the hematological malignancies. These T cells are capable of selectively recognizing tumor-associated antigens. There are a variety of reported, as well as ongoing studies on the utilization of CAR-T cells in the treatment of leukemia, myeloma, as well as B and T cell lymphomas. In this review, we aimed to highlight current understanding of this promising treatment modality, including its efficacy and adverse effects.

嵌合抗原受体T细胞在恶性血液疾病中的治疗
摘要：
过继T细胞通过嵌合抗原受体修饰后(CARs)是一种对抗血液恶性肿瘤非常令人鼓舞的治疗方式。这些T细胞能够选择性的识别肿瘤相关抗原。这里有很多的报告，以及正在进行中的利用CAR-T细胞对抗白血病、骨髓瘤以及B、T细胞淋巴瘤的研究。在这篇综述中，我们的目的是强调对于这种有治疗前景的方案的理解，包括其疗效和不良反应。
技术资料分享自爱康得生物技术